Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. - Test2 - elhamkhani - TriplyDB

Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis.

Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis.

http://www.wikidata.org/entity/Q30439686

about

Proteomics and peptidomics: moving toward precision medicine in urological malignancies The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy Biomarkers for non-muscle invasive bladder cancer: Current tests and future promise Applications of urinary proteomics in biomarker discovery Early diabetic nephropathy in type 1 diabetes: new insights Proteomic candidate biomarkers of drug-induced nephrotoxicity in the rat Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy Urinary proteomics to support diagnosis of stroke Evaluation of the Zucker diabetic fatty (ZDF) rat as a model for human disease based on urinary peptidomic profiles Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study Seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease Proteomic Analysis of Vitreous Humor in Retinal Vein Occlusion Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy PICquant: a quantitative platform to measure differential peptide abundance using dual-isotopic labeling with 12C6- and 13C6-phenyl isocyanate Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease.Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics.Discovery and validation of urinary biomarkers for prostate cancer Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments Integration of biosensors and drug delivery technologies for early detection and chronic management of illness Saliva analysis by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF/MS): from sample collection to data analysis.Classical MALDI-MS versus CE-based ESI-MS proteomic profiling in urine for clinical applications.The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins.A new strategy for faster urinary biomarkers identification by Nano-LC-MALDI-TOF/TOF mass spectrometry.Adapting mass spectrometry-based platforms for clinical proteomics applications: The capillary electrophoresis coupled mass spectrometry paradigm.Liquid chromatography-mass spectrometry: a tool for proteome analysis and biomarker discovery and validation.Approaching clinical proteomics: current state and future fields of application in fluid proteomics.Multivariate classification of urine metabolome profiles for breast cancer diagnosis Application of Proteomic Analysis to Renal Disease in the Clinic.Proteomics of vitreous humor of patients with exudative age-related macular degeneration High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine Mass spectrometry and renal calculi Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria Addressing the challenge of defining valid proteomic biomarkers and classifiers.Serum peptidome profiling in patients with gastric cancer.Assessment of high-throughput high-resolution MALDI-TOF-MS of urinary peptides for the detection of muscle-invasive bladder cancer.Fibrinogen alpha chain precursor and apolipoprotein A-I in urine as biomarkers for noninvasive diagnosis of calcium oxalate nephrolithiasis: a proteomics study Phosphoric acid functionalized mesoporous organo-silica (EPO) as the adsorbent for in situ enrichment and isotope labeling of endogenous phosphopeptides.

P2860

Q26749401-A755A6CB-65BD-4F43-8709-0E1D433EF286 Q26752555-FA459EAB-4874-4B2A-91FC-708479737EB5 Q26775990-A797B41E-CF1F-46B8-B0B2-A15E84873495 Q27010368-3742CA76-D470-4708-95FE-19CA0D8524B8 Q27021632-0AF8871E-F1FB-490E-A4D8-38A67A7DFA3E Q27305109-835F903D-DB76-415A-9787-3BA5574B0757 Q28475613-6FFFEC14-F2C3-42E6-9854-E7841B6DC671 Q28477629-5ECDF692-66DE-4991-9424-38AAE4B2011C Q28478586-25AC4091-200F-41FA-9C26-256EE2B94568 Q28483776-A009DC4A-92B0-489B-B5F1-A98A36CD1152 Q28484239-5D374FA0-4BC6-4F6C-BDF8-D02C75E30898 Q28484968-79168AF7-3081-4073-9239-58C17B667ACD Q28534235-0305C40B-6E28-4F72-93F7-26727A57D426 Q28552292-774A6153-0B8D-4AE2-8E35-99AB514A533F Q28748796-2678B58F-A07A-4527-A8D3-A83B0924E828 Q30428469-081F7FA8-D8DD-4BC3-B30A-0321917F3EE5 Q30430034-05348631-C6C3-493E-8EFA-53797ADB1F2A Q30434677-DFDF43F4-5A48-4BD5-B0F7-52499C15B03D Q30437141-515E1558-2680-4A94-9AEB-2A2893FCD5CB Q30438582-84B9D374-CECC-4BBD-9CAF-F59FB5177102 Q30438814-68E2EF38-9A02-4492-96B0-4F49D9A8AA76 Q30451853-2C685864-902C-401E-98A1-EB38FFB582B9 Q31136934-2E7A71A5-C852-4332-B9FF-A10421EEB181 Q31148183-1006CE19-FBBB-47CD-AE92-5D0F10AF10AE Q33256124-DC5823CB-2BD2-4265-A245-4E9D9C4EC2AC Q33384944-BC35937D-E30E-4ADA-A0E6-9E10FB9383B8 Q33436829-1FF84CBC-1E1A-402E-A818-DD40E732B72C Q33457379-38988A4B-9781-4D53-8B61-FF2C7FC78A77 Q33467523-3EAECD28-C68A-442A-9DF6-98A4734EDECC Q33560536-CD2F11CE-4823-40E8-A736-7A4D833D02D3 Q33575004-933ACFB0-FBA2-439C-99D5-01DB9E65430B Q33610106-52C630CC-2DD7-477D-AFBC-A3AF1FA3239B Q33610197-FA5C7461-DA1E-4C7B-A13A-C1CF649BE46B Q33725902-34EC2E3B-89AB-4E4F-A7BF-DD76FAA77CE1 Q33735287-487E7A31-6406-4F07-B8CC-996516F88A5B Q33786157-143364D9-0101-46BB-8E11-562B4F25009A Q33955495-DE033E91-F93C-4673-848D-F29CA663CF66 Q33976936-EB488231-7FCE-499C-A6E0-9B1B4C88102C Q34043307-A7969AAF-1961-48E5-9E65-3252CC8FB43C Q34066505-99C7C684-C2F8-42C8-ADBB-2890BFA468F5

P2860

Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis.

http://www.wikidata.org/entity/Q30439686

description

2006 nî lūn-bûn

@nan

2006 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մարտին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Discovery and validation of ne ...... ancer: a prospective analysis.

@ast

Discovery and validation of ne ...... ancer: a prospective analysis.

@en

type

label

Discovery and validation of ne ...... ancer: a prospective analysis.

@ast

Discovery and validation of ne ...... ancer: a prospective analysis.

@en

prefLabel

Discovery and validation of ne ...... ancer: a prospective analysis.

@ast

Discovery and validation of ne ...... ancer: a prospective analysis.

@en

P1433

Q30439686-861EF6E7-3A61-4B2A-9769-65CEFF83E3E3

P1476

Q30439686-E8C6A61F-263A-4B18-A251-0D3125893491

P2093

Q30439686-372BB83A-9116-4CD5-8640-938BAB36D46C

Q30439686-47267D73-5903-4E02-B21F-E761FADE15B2

Q30439686-58DB0032-DA0A-4CE9-B85A-AD996F7C8A50

Q30439686-6FB76F84-2F7C-4DB1-8F2A-4D6DBF3B4CC9

Q30439686-830D56EF-B4E2-437B-9280-1EE6C2C043CF

Q30439686-8C6AF9C5-FDA0-4C81-B7D3-7BA831CAE30F

Q30439686-FF07AECC-100B-4202-8458-24778D175F07

P304

Q30439686-F5A8301E-B9C7-4629-9CA2-CB745E6E9F85

P31

Q30439686-F1ABE4D9-3BC1-436F-A9FE-2D0094F4FEA6

P356

Q30439686-D1860C5B-F7EA-4ED7-86BB-0F8F3BF314E5

P433

Q30439686-2D11FA09-A029-4FAB-9081-2118EE20384C

P478

Q30439686-042FDAFA-4C2B-47DC-8102-FA77FF03F600

P50

Q30439686-1E6CBAF4-AEB0-49DF-9EF0-ECC94886FC33

P577

Q30439686-445198A0-86A1-4A8D-B4EA-B4BA86CAA91C

P698

Q30439686-577F4200-7CDA-45EC-A97E-A8AC8902A316

P921

Q30439686-C21F9F3E-B324-46D3-B6DC-D86441FC4CA2

P356

S1470-2045(06)70584-8

P1433

The Lancet Oncology

P1476

Discovery and validation of ne ...... ancer: a prospective analysis.

@en

P2093

Dan Theodorescu

http://www.w3.org/2001/XMLSchema#string

Henry F Frierson

http://www.w3.org/2001/XMLSchema#string

Ingo Just

http://www.w3.org/2001/XMLSchema#string

Mark Conaway

http://www.w3.org/2001/XMLSchema#string

Mark M Ross

http://www.w3.org/2001/XMLSchema#string

Michael Walden

http://www.w3.org/2001/XMLSchema#string

Stefan Wittke

http://www.w3.org/2001/XMLSchema#string

P304

230-240

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(06)70584-8

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16510332

http://www.w3.org/2001/XMLSchema#string

P921